[Diagnostic Value of IGF-I, β2-MG and SF for Patients with Multiple Myeloma and Their Relationship with Clinical Staging].

Objective: To investigate the diagnostic value of insulin like growth factor I(IGF-I), β2-microglobulin (β2MG) and serum ferritin (SF) in patients with multiple myeloma (MM) and their ralationship with clinical staging.

Methods: Seventy-seven patients with MM treated in Depertment of Hematology of Shanghai 10th hospital and Oncology of Shanghai Armed Police Hospital from August 2016 to June 2017 were enrolled in MM group, at same period 77 healthy volunteers were enrolled in normal control group. The diagnostic value of IGF-I, β2-MG and SF for MM, and their levels in different stages of MM were compared.

[Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].

The outcomes for the patients with multiple myeloma (MM) have been improved substantially in both progression-free survival and overall survival in the past decade. Many patients are now achieving a complete response to treatments. Extensive data indicate that the information about minimal residual disease (MRD) can be used potentially as a biomarker to evaluate the efficacy of different treatment strategies instead of overall survival.

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.

Natural killer/T-cell lymphoma (NKTCL) is a malignant proliferation of CD56(+) and cytoCD3(+) lymphocytes with aggressive clinical course, which is prevalent in Asian and South American populations. The molecular pathogenesis of NKTCL has largely remained elusive. We identified somatic gene mutations in 25 people with NKTCL by whole-exome sequencing and confirmed them in an extended validation group of 80 people by targeted sequencing.

Lymphocyte subsets in primary immune thrombocytopenia.

The aim of this study was to explore the clinical significance of T-lymphocyte subsets in the peripheral blood of patients with adult primary immune thrombocytopenia (ITP) in an active phase. T-lymphocyte subsets in the peripheral blood of 90 ITP patients in the active phase and 59 normal controls were detected by flow cytometry. ITP patients were treated with a conventional dose of corticosteroids, and therapeutic response was evaluated after 3 months.

[Inhibiting effect of CaMKIIN up-regulation on leukemia cells growth and its mechanism].

Objective: To investigate the inhibitory effects of CaMKIIN on acute myeloid leukemia cell line HL-60 to explore a novel therapeutic target of leukemia.

Methods: Human CaMK II N gene expression vector pcDNA3.1/hCaMKIIN or empty vector pcDNA3.

[Expression of 11β-hydroxysteroid dehydrogenase type 2 in lymphoblastic cells and its relationship with glucocorticoid sensitivity].

This study was aimed to explore the expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in 3 different lymphoblastic cell lines with relation to their glucocorticoid (GC) sensitivity. The 11β-HSD2 expressions in acute lymphoblastic leukemia Jurkat cells, lymphoma Daudi and Raji cells, and peripheral blood T cells of a healthy volunteer were analyzed by real time PCR and Western blot. Glucocorticoid (GC)-induced apoptosis in 3 different cell lines was detected by flow cytometry.

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) was highly and universally expressed on myeloma cells while having restricted expression in normal tissues. Elotuzumab (formerly known as HuLuc63), a humanized mAb targeting CS1, is currently in a phase I clinical trial in relapsed/refractory myeloma.